title: CCR 20th anniversary commentary: Radioactive Drones for B-cell lymphoma.
abstract: In a study published in the March 1, 1996, issue of Clinical Cancer Research, Knox and colleagues (1) demonstrated the safety and efficacy of Yttirium-90 ((90)Y)-anti-CD20 monoclonal antibody therapy, as well as the benefit of preinfusion of unlabeled antibody on radiolabeled antibody biodistribution. Subsequent clinical trials with this radiolabeled antibody led to regulatory approval of this treatment for B-cell lymphoma. See related article by Knox et al., Clin Cancer Res 1996;2(3) Mar 1996; 457-70.
authors: Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California. sknox@stanford.edu.
authors: Susan J
authors: SJ
authors: Knox
authors: Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, California.
authors: Ronald
authors: R
authors: Levy
mesh_terms: D000818:Animals; D006801:Humans; D016393:Lymphoma, B-Cell / Q000532:radiotherapy; D016499:Radioimmunotherapy